Mitochondrial Diseases

• Impaired Electron Transport Chain (ETC) Function: The mitochondrial ETC consists of five protein complexes (I-V) embedded in the inner mitochondrial membrane. mtDNA encodes 13 proteins essential for ETC function (subunits of Complexes I, III, IV, and V) plus 22 transfer RNAs and 2 ribosomal RNAs necessary for synthesis of these proteins. Mutations affecting Complex I (NADH dehydrogenase), III (cytochrome bc1 complex), or IV (cytochrome c oxidase) most commonly produce severe disease. When ETC function is compromised, electron transfer is blocked, preventing efficient coupling of proton pumping to electron flow. This reduces the proton gradient across the inner mitochondrial membrane, directly decreasing ATP synthesis via ATP synthase (Complex V). For example, mutations in MT-CO1 (encoding cytochrome c oxidase subunit I) or MT-ND1 (Complex I subunit) frequently cause severe infantile-onset disease with lactic acidosis and multi-organ involvement. The energy deficit is particularly severe in tissues requiring continuous ATP generation: neurons (which cannot store energy), cardiac myocytes, and skeletal myocytes exhibiting high oxidative metabolism.

• Oxidative Stress and Secondary Damage: Impaired ETC function paradoxically increases production of reactive oxygen species (ROS), particularly superoxide anions generated at Complexes I and III when electron transfer is blocked. Normally, electrons flow rapidly through the chain to oxygen, which is reduced to water; in dysfunctional mitochondria, electrons leak to molecular oxygen, forming superoxide. ROS accumulation overwhelms antioxidant defenses (superoxide dismutase, catalase, glutathione peroxidase), causing lipid peroxidation of the inner mitochondrial membrane, DNA damage (both mtDNA and nuclear DNA), and protein cross-linking. This secondary oxidative damage explains the paradox that mitochondrial diseases feature both energy deficit and toxic damage. Tissues with high metabolic rates (brain, muscle, heart) are most vulnerable because they generate the most ROS and have the highest dependence on ATP. This oxidative stress contributes to progressive neurodegeneration, cardiomyopathy, and hepatic failure observed in mitochondrial syndromes.

• Lactic Acidosis as a Pathophysiologic Marker: When mitochondrial ATP production fails, cells become increasingly dependent on anaerobic glycolysis via lactate fermentation to maintain ATP homeostasis. Under normal conditions, pyruvate formed from glycolysis enters mitochondria and is oxidized via the tricarboxylic acid (TCA) cycle. However, in mitochondrial disease, pyruvate accumulates and is shunted toward lactate production by lactate dehydrogenase (LDH). Lactate accumulates systemically, producing the characteristic lactic acidosis observed in many mitochondrial syndromes. Lactic acidosis is both a marker of severe mitochondrial dysfunction and a cause of further cellular damage (interfering with protein synthesis, ion pump function, and neuronal signaling). The severity of lactic acidosis often correlates with disease severity and prognosis. Additionally, accumulated NADH (generated during glycolysis) inhibits TCA cycle enzymes, reducing flux through the cycle and contributing to elevated lactate and alanine levels.

• Genetic Heterogeneity and Maternal Inheritance: mtDNA mutations follow maternal (matrilineal) inheritance because mitochondria are inherited exclusively from the ovum during fertilization (sperm mitochondria are actively eliminated after fertilization via ubiquitin-mediated autophagy). mtDNA is present in hundreds to thousands of copies per mitochondrion, and cells may contain a mixture of mutant and wild-type mtDNA—a condition called heteroplasmy. The proportion of mutant mtDNA (mutant load or heteroplasmy level) determines whether cellular ATP production is compromised; a threshold effect typically occurs when mutant mtDNA exceeds 60-90% of total mtDNA, below which oxidative phosphorylation remains sufficient. This heteroplasmic distribution explains variable penetrance and phenotypic severity both between families and among siblings from the same affected mother. During oogenesis, random segregation of mitochondria can cause dramatic shifts in heteroplasmy levels between mother and offspring, explaining severe disease in children of mildly affected or asymptomatic mothers. Nuclear DNA mutations encoding mitochondrial proteins (>1,500 proteins are imported into mitochondria) follow Mendelian inheritance patterns and often cause severe early-onset disease. Important nuclear-encoded examples include POLG (mitochondrial DNA polymerase gamma, causing Alpers-Huttenlocher syndrome), DGUOK (deoxyguanosine kinase), and genes encoding respiratory chain subunits.

• Tissue-Specific Threshold Effects and Progressive Accumulation of Mutations: Tissues with the highest ATP demands (brain, muscle, heart, liver, kidney) are affected first and most severely. The threshold effect describes the observation that oxidative phosphorylation typically remains sufficient until mutant mtDNA exceeds 60-90%; below this level, wild-type mtDNA can produce adequate ATP. However, this threshold varies by tissue (muscle requires higher ATP and has a lower threshold), by specific mutation (some mutations are more deleterious than others), and by tissue energy demands. Over time, additional age-related mtDNA mutations accumulate, and selective expansion of mutant mtDNA in certain tissues (due to replicative advantage of certain mutations) can cause progressive decline. This explains why mitochondrial diseases often manifest with progressive symptoms despite stable nuclear DNA genotype—the heteroplasmy level shifts with age and tissue selective pressure.

• Impaired Calcium Homeostasis: The mitochondrial electron transport chain generates the proton gradient that drives ATP synthase and also drives mitochondrial calcium uptake via the mitochondrial calcium uniporter. In mitochondrial disease with ETC dysfunction, both ATP production and calcium handling are impaired. Mitochondria cannot sequester excess cytoplasmic calcium, leading to increased cytoplasmic free calcium concentration and triggering calcium-dependent proteases (calpains), endonucleases, and apoptotic pathways. Calcium dysregulation particularly affects neurons, where appropriate calcium signaling is essential for synaptic plasticity and neuronal survival. Additionally, impaired mitochondrial calcium buffering reduces ATP production even further (calcium regulation requires ATP), creating a vicious cycle.

• mtDNA Point Mutations and Deletions: Single nucleotide mutations in mtDNA genes encoding respiratory chain proteins are the most common cause of primary mitochondrial disease. MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, Stroke-like episodes) is classically associated with the m.3243A>G mutation in the MT-TL1 gene (tRNA leucine), which impairs mitochondrial protein synthesis and particularly affects Complexes I and IV activity. This mutation exhibits heteroplasmy and maternal inheritance; clinical severity correlates with mutant load in muscle. The m.8344A>G and m.8356A>G mutations in MT-TK (tRNA lysine) cause MERRF (Myoclonic Epilepsy with Ragged-Red Fibers), characterized by myoclonus, seizures, and progressive myopathy. NARP (Neuropathy, Ataxia, Retinitis Pigmentosa) and Leigh syndrome can result from mutations in MT-ATP6 and MT-ATP8 (ATP synthase subunits), with m.8993T>G being particularly common in Leigh syndrome. Large-scale deletions of mtDNA (ranging from 0.5 to 7 kb) typically cause Kearns-Sayre Syndrome (KSS) and Progressive External Ophthalmoplegia (PEO) with earlier and more severe presentation than point mutations. Deletions usually arise sporadically and are less commonly transmitted maternally, though maternal transmission of deletion-prone mtDNA can occur.

• Nuclear DNA Mutations Encoding Respiratory Chain Subunits: Mutations in nuclear genes encoding the ~80 respiratory chain subunits and assembly factors cause severe, often childhood-onset disease with variable organ involvement. POLG mutations (encoding mitochondrial DNA polymerase gamma) cause Alpers-Huttenlocher syndrome (progressive neurodegeneration, status epilepticus, liver failure in infants) and ataxia-neuropathy spectrum disorders in older children and adults. POLG mutations impair mtDNA replication and cause selective mtDNA depletion in affected tissues. DGUOK mutations (deoxyguanosine kinase) cause hepatocerebral mitochondrial disease with early-onset liver failure and neurological decline. Mutations in genes encoding Complex I assembly factors (ACAD9, NDUFAF genes) and Complex IV assembly factors (COX10, COX11) produce severe early-onset disease. These nuclear mutations typically follow autosomal recessive inheritance and often present in infancy with multisystem involvement.

• mtDNA Depletion Syndromes: Characterized by profound reduction in mtDNA copy number (often <5% of normal) despite normal nuclear DNA content. Caused by mutations in genes controlling mtDNA replication, nucleotide metabolism, or mitochondrial maintenance (POLG, DGUOK, TK2, SUCLA2, SUCLG1, TYMP). Hepatocerebral form presents in infants with liver failure progressing to encephalopathy. Myopathic form causes infantile-onset myopathy with proximal weakness and respiratory insufficiency. Neurogastrointestinal form (MNGIE syndrome, due to TYMP mutations) presents with gastrointestinal dysmotility, peripheral neuropathy, and leukoencephalopathy.

• Secondary Mitochondrial Disease: Acquired mitochondrial dysfunction occurs in numerous conditions: stavudine and didanosine (nucleoside reverse transcriptase inhibitors, NRTIs) cause mtDNA depletion; valproic acid impairs mitochondrial β-oxidation and depletes carnitine; linezolid and chemotherapy agents (doxorubicin, cisplatin) cause mitochondrial toxicity; severe illness (sepsis, hypoxia) impairs ETC function; aging is associated with progressive accumulation of mtDNA mutations and oxidative damage; and diabetes and neurodegenerative diseases (Parkinson's, Alzheimer's) feature mitochondrial dysfunction.

• Risk Factors for Phenotypic Expression: Beyond genotype, heteroplasmy level, age, exercise (which increases ATP demand), acute illness, infections (which upregulate energy metabolism), certain medications, and metabolic stress influence whether genetically predisposed individuals manifest disease.

Cardinal Neurological Manifestations

• Seizures: Occur in 30-80% of mitochondrial disease patients and are often refractory to standard antiepileptic drugs. Seizures reflect impaired neuronal ATP production and calcium dysregulation. May present as infantile spasms (West syndrome), generalized tonic-clonic seizures, myoclonus (particularly in MERRF), or absences. Seizures often worsen during metabolic stress (infection, exercise, fasting). Status epilepticus is a life-threatening presentation in Alpers-Huttenlocher syndrome.

• Progressive Encephalopathy and Cognitive Decline: Developmental delay (in childhood-onset disease) or progressive dementia (in adult-onset disease) reflects neuronal energy failure and accumulation of oxidative damage. Cognitive decline may be accompanied by behavioral changes, personality alterations, or psychosis. The pattern can be global cognitive decline or focal impairments depending on which brain regions are predominantly affected.

• Stroke-like Episodes (MELAS): Distinguished from typical ischemic stroke by occurrence in young patients without vascular risk factors, lack of correspondence to vascular territories, and often reversible imaging abnormalities. Results from mitochondrial angiopathy (mitochondrial dysfunction in vascular smooth muscle causing vasospasm and impaired vascular autoregulation) and neuronal energy failure rather than thrombotic occlusion. Typically present with acute focal neurological deficits (hemiparesis, hemianopsia, aphasia) that may be transient. Characteristic imaging shows cortical signal abnormalities on diffusion-weighted imaging that do not respect arterial distributions and may progress or resolve unexpectedly.

• Progressive Myopathy: Typically affects proximal muscles more than distal. Presents with weakness, reduced exercise tolerance, progressive immobility, and respiratory compromise if respiratory muscles are involved. Muscle biopsy classically shows ragged-red fibers (muscle fibers with abnormal subsarcolemmal mitochondrial accumulation due to mtDNA proliferation), though ragged-red fibers are not present in all mitochondrial myopathies. Myalgia and fatigue are prominent. Unlike typical muscular dystrophies, mitochondrial myopathy often worsens with exercise (exercise intolerance) rather than remaining static, because high energy demands exceed ATP supply.

• Progressive External Ophthalmoplegia (PEO): Symmetric, bilateral ptosis and ophthalmoplegia (impaired vertical gaze and horizontal eye movements) due to mitochondrial myopathy affecting extraocular muscles. Often the earliest manifestation in KSS and other deletion syndromes. Patients develop restrictive ophthalmoplegia with preserved pupillary responses (no CN III, IV, VI lesions—the deficit is muscular). Progressive over years, leading to essentially complete external ophthalmoplegia and requiring head positioning to maintain vision.

Cardiac Manifestations

• Hypertrophic or Dilated Cardiomyopathy: Results from mitochondrial myopathy affecting cardiac myocytes. Hypertrophic cardiomyopathy may present with dyspnea, chest pain, syncope, or sudden cardiac death from arrhythmias. Dilated cardiomyopathy presents with heart failure symptoms (orthopnea, paroxysmal nocturnal dyspnea, edema, fatigue). Cardiac involvement worsens prognosis significantly.

• Conduction System Abnormalities: Atrioventricular (AV) blocks, sick sinus syndrome, and ventricular arrhythmias are common. Mitochondrial disease should be suspected in young patients with unexplained AV block. Sudden cardiac death is a recognized complication.

Hepatic Involvement

• Acute Liver Failure (Alpers-Huttenlocher Syndrome): Presents in infants with progressive hepatomegaly, jaundice, coagulopathy, and encephalopathy. Acute decompensation is often triggered by febrile illness or vaccinations. Liver biopsy shows microvesicular steatosis and hepatocyte necrosis. Prognosis is poor; fulminant hepatic failure typically develops by age 2-3 years.

• Chronic Progressive Liver Disease: Less severe hepatic involvement presents with hepatomegaly, slowly progressive cirrhosis, and eventually portal hypertension and hepatic synthetic failure.

Renal and Metabolic Manifestations

• Renal Tubular Dysfunction: Fanconi syndrome (proximal tubular dysfunction causing phosphaturia, glycosuria, hyperaminoaciduria, renal tubular acidosis) occurs in some mitochondrial diseases (especially mitochondrial cytochrome c oxidase deficiency). Results from impaired ATP-dependent tubular reabsorption.

• Lactic Acidosis: Often asymptomatic at rest but becomes profound during acute illness or exercise. Manifests as tachypnea, altered mental status, and hemodynamic instability. Plasma lact

Inheritance rules examiners test

• Maternal (matrilineal) transmission only: an affected father never transmits mtDNA disease — the fastest way to exclude X-linked recessive (where fathers transmit to all daughters) and autosomal patterns on a pedigree. All children of an affected mother are at risk, but severity varies.
• Heteroplasmy + threshold effect: explains variable expressivity within one sibship. The common distractor is "incomplete penetrance" or "imprinting" — the stem wants heteroplasmy with mitotic segregation.

Syndrome–buzzword pairs

• MELAS: young patient, stroke-like deficit not confined to a vascular territory, lactic acidosis, seizures, short stature, sensorineural hearing loss, diabetes; tRNA-Leu m.3243A>G.
• MERRF: myoclonus plus ragged-red fibers on modified Gomori trichrome (tRNA-Lys m.8344A>G).
• Leber hereditary optic neuropathy: subacute painless bilateral central vision loss in a young adult, often homoplasmic with male predominance — a mitochondrial disease without lactic acidosis or myopathy.
• Kearns–Sayre: PEO + pigmentary retinopathy + cardiac conduction block, from a single large mtDNA deletion (usually sporadic).

Best next steps

• Suspected MELAS: targeted mtDNA testing for m.3243A>G; because heteroplasmy is low in blood leukocytes, urinary epithelial cells or buccal/muscle tissue are preferred — a negative blood test does not exclude disease (Mitochondrial Medicine Society consensus).
• Kearns–Sayre or any mitochondrial myopathy: serial ECG/echo surveillance, and permanent pacing for advanced conduction disease per the ACC/AHA/HRS bradycardia guideline, which treats neuromuscular conduction disease as unpredictable and rapidly progressive.

Drug pitfalls

• Valproate: avoid in suspected mitochondrial epilepsy — FDA carries a contraindication in *POLG*-related disorders because of fatal hepatotoxicity. Choose an alternative antiseizure agent.
• Metformin (lactic acidosis risk), aminoglycosides (profound ototoxicity with the MT-RNR1 m.1555A>G variant), and NRTIs such as stavudine/didanosine (mtDNA depletion) are the classic offenders.

• Therapy reality check: management is largely supportive — cofactor "cocktails" (coenzyme Q10, riboflavin, L-carnitine) and IV L-arginine for MELAS stroke-like episodes are used but rest on limited evidence; do not select a curative option.